Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) – HC Wainwright decreased their FY2026 earnings estimates for shares of Tyra Biosciences in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.64) per share for the year, down from their prior estimate of ($2.60). HC Wainwright currently has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.44) EPS.
TYRA has been the topic of a number of other reports. Wedbush raised their price target on Tyra Biosciences from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, William Blair raised Tyra Biosciences to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.40.
Read Our Latest Stock Report on TYRA
Tyra Biosciences Trading Down 5.8%
Shares of TYRA stock opened at $19.76 on Friday. The firm has a fifty day moving average price of $21.85 and a 200 day moving average price of $29.44. Tyra Biosciences has a 12 month low of $14.67 and a 12 month high of $40.65.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07).
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC raised its stake in Tyra Biosciences by 843.4% during the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock worth $27,000 after acquiring an additional 1,088 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Tyra Biosciences by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company’s stock valued at $239,000 after acquiring an additional 1,424 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Tyra Biosciences by 10.7% in the first quarter. Public Employees Retirement System of Ohio now owns 20,522 shares of the company’s stock valued at $786,000 after acquiring an additional 1,980 shares in the last quarter. State of Wyoming acquired a new position in Tyra Biosciences in the second quarter valued at $76,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Tyra Biosciences in the third quarter valued at $67,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
Tyra Biosciences Company Profile
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
